Secondary analysis of the phase 3 ADRIATIC trial (530 patients, limited-stage SCLC): durvalumab vs placebo after chemoradiotherapy gave OS hazard ratios generally favouring durvalumab across chemotherapy, radiotherapy and PCI subgroups, with no significant interactions.
Secondary analysisn = 530
Senan et al. Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial